AnaptysBio (0HFQ) Ratios
AnaptysBio Ratios
GB:0HFQ's free cash flow for Q2 2026 was $-26.62M. For the 2026 fiscal year, GB:0HFQ's free cash flow was increased by $17.00K and operating cash flow was $-26.64M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 |
| Quick Ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 |
| Cash Ratio | 6.17 | 2.71 | 0.96 | 2.74 | 30.79 |
| Solvency Ratio | -0.03 | -0.35 | -0.45 | -0.36 | -0.19 |
| Operating Cash Flow Ratio | 0.51 | -2.98 | -3.23 | -2.82 | -2.85 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -70.30 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 23.07M | $ 18.91M | $ 42.55M | $ 98.92M | $ 267.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.76 | 0.04 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.38 | 5.21 | 0.20 | 0.07 | 0.06 |
| Debt-to-Capital Ratio | 0.27 | 0.84 | 0.17 | 0.07 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 0.83 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 9.79 | 6.83 | 5.13 | 2.33 | 1.80 |
| Debt Service Coverage Ratio | 0.86 | -1.78 | -8.65 | -4.99 | -38.42 |
| Interest Coverage Ratio | 0.60 | -2.29 | -9.09 | -5.46 | -39.18 |
| Debt to Market Cap | 0.01 | 1.42 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.38 | 14.78 | 1.33 | 1.44 | 0.82 |
| Net Debt to EBITDA | -3.24 | -2.66 | 0.12 | 0.49 | 8.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 98.97% | -79.49% | -671.01% | -763.21% | -55.91% |
| EBIT Margin | 28.48% | -104.23% | -915.50% | -1045.90% | -91.49% |
| EBITDA Margin | 29.52% | -101.60% | -911.70% | -1023.20% | -88.18% |
| Operating Profit Margin | 20.42% | -125.93% | -958.27% | -1119.41% | -89.93% |
| Pretax Profit Margin | -5.57% | -159.10% | -953.68% | -1251.09% | -91.49% |
| Net Profit Margin | -5.64% | -159.10% | -953.66% | -1251.33% | -91.49% |
| Continuous Operations Profit Margin | -5.64% | -159.10% | -953.66% | -1251.33% | -91.49% |
| Net Income Per EBT | 101.25% | 100.00% | 100.00% | 100.02% | 100.00% |
| EBT Per EBIT | -27.28% | 126.34% | 99.52% | 111.76% | 101.73% |
| Return on Assets (ROA) | -3.63% | -30.02% | -36.17% | -21.09% | -8.99% |
| Return on Equity (ROE) | -35.56% | -204.93% | -185.71% | -49.11% | -16.22% |
| Return on Capital Employed (ROCE) | 14.70% | -26.22% | -39.62% | -19.71% | -9.06% |
| Return on Invested Capital (ROIC) | 14.61% | -26.11% | -39.45% | -19.65% | -9.04% |
| Return on Tangible Assets | -3.63% | -30.02% | -36.17% | -21.09% | -8.99% |
| Earnings Yield | -1.47% | -57.95% | -28.37% | -14.75% | -6.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.93 | 2.24 | 2.50 | 7.25 | 72.12 |
| Payables Turnover | 0.63 | 40.94 | 28.16 | 31.90 | 56.57 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 16.89 | 5.62 | 0.94 | 0.51 | 2.89 |
| Asset Turnover | 0.64 | 0.19 | 0.04 | 0.02 | 0.10 |
| Working Capital Turnover Ratio | 0.67 | 0.24 | 0.04 | 0.02 | 0.14 |
| Cash Conversion Cycle | -530.46 | 154.09 | 132.79 | 38.90 | -1.39 |
| Days of Sales Outstanding | 52.66 | 163.01 | 145.75 | 50.35 | 5.06 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 583.13 | 8.92 | 12.96 | 11.44 | 6.45 |
| Operating Cycle | 52.66 | 163.01 | 145.75 | 50.35 | 5.06 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.71 | -4.77 | -4.49 | -2.61 | -1.67 |
| Free Cash Flow Per Share | 0.71 | -4.78 | -4.52 | -2.63 | -1.72 |
| Dividend Paid and CapEx Coverage Ratio | 226.40 | -378.04 | -149.69 | -205.57 | -33.62 |
| Capital Expenditure Coverage Ratio | 226.40 | -378.04 | -149.69 | -205.57 | -33.62 |
| Operating Cash Flow Coverage Ratio | 1.40 | -0.37 | -6.78 | -3.78 | -2.19 |
| Operating Cash Flow to Sales Ratio | 0.08 | -1.48 | -7.04 | -7.15 | -0.73 |
| Free Cash Flow Yield | 2.18% | -54.15% | -21.09% | -8.47% | -4.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -70.26 | -1.72 | -3.52 | -6.78 | -16.49 |
| Price-to-Sales (P/S) Ratio | 3.83 | 2.75 | 33.61 | 84.85 | 15.09 |
| Price-to-Book (P/B) Ratio | 24.14 | 3.54 | 6.55 | 3.33 | 2.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 45.80 | -1.85 | -4.74 | -11.80 | -20.16 |
| Price-to-Operating Cash Flow Ratio | 45.60 | -1.85 | -4.77 | -11.86 | -20.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.77 | 0.11 | -0.11 | -0.06 | -0.09 |
| Enterprise Value Multiple | 9.73 | -5.36 | -3.57 | -7.80 | -8.59 |
| Enterprise Value | 674.06M | 497.00M | 558.56M | 820.98M | 478.45M |
| EV to EBITDA | 9.73 | -5.36 | -3.57 | -7.80 | -8.59 |
| EV to Sales | 2.87 | 5.44 | 32.56 | 79.81 | 7.57 |
| EV to Free Cash Flow | 34.37 | -3.66 | -4.59 | -11.10 | -10.12 |
| EV to Operating Cash Flow | 34.22 | -3.67 | -4.62 | -11.16 | -10.42 |
| Tangible Book Value Per Share | 1.34 | 2.50 | 3.27 | 9.31 | 12.99 |
| Shareholders’ Equity Per Share | 1.34 | 2.50 | 3.27 | 9.31 | 12.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 8.44 | 3.22 | 0.64 | 0.37 | 2.30 |
| Net Income Per Share | -0.48 | -5.12 | -6.08 | -4.57 | -2.11 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.20 | 1.53 | 1.04 | 1.20 | 1.00 |
| Research & Development to Revenue | 0.58 | 1.79 | 8.14 | 8.63 | 1.56 |
| SG&A to Revenue | 0.22 | 0.46 | 2.44 | 3.56 | 0.34 |
| Stock-Based Compensation to Revenue | 0.15 | 0.37 | 1.94 | 2.66 | 0.24 |
| Income Quality | 0.40 | 0.93 | 0.74 | 0.57 | 0.79 |
Currency in USD